Noticias ProSomnus Inc - OSA | Acciones NASDAQ

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP...

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the...

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the...

ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP...

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA

PLEASANTON, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the...

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the...

ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea

PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the...

Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices

PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the...

ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results

PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the...

ProSomnus Announces Third Quarter 2023 Investor Call and Business Update

PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference

PLEASANTON, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a...

ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations

PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a...

ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences

PLEASANTON, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea

Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an...

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

PLEASANTON, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”...

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

ProSomnus Inc (OSA)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

OSA Noticias

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea

Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices

ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results

ProSomnus Announces Third Quarter 2023 Investor Call and Business Update

ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference

ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations

ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences

Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

OSA Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

ProSomnus Inc (OSA) Noticias

ProSomnus Inc (OSA)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

OSA Noticias

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea

Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices

ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results

ProSomnus Announces Third Quarter 2023 Investor Call and Business Update

ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference

ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations

ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences

Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

OSA Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación